Low IgE monoclonal gammopathy level in serum highlights 20‐yr survival in a case of IgE multiple myeloma

Hayes, M.; Carey, John; Krauss, John C.; Hedstrom, Deborah; Gulbranson, Ronald; Keren, David F.

doi:10.1111/j.1600-0609.2007.00825.x

Cited by 12 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the previous reports, 8 out of 30 patients survived for longer than 2 years. Hayes et al reported a patient showing 20-year survival, the longest in our reviewed literature [5]. Even though the present patient was free of specific symptoms at the time of diagnosis, he had been started on combination chemotherapy (doxorubicin, cyclophosphamide, melphalan, and prednisone) and received intermittent treatment of MP for several years.…”

Section: Discussionmentioning

confidence: 62%

“…Since the initial report by Johansson and Bennich in 1967 [1], only 47 IgE-multiple myeloma (MM) cases have been reported [2][3][4][5][6][7][8][9]. Unique clinical features such as a higher frequency of plasma cells in the peripheral blood, a high incidence of osteosclerotic (osteoblastic) change, and hepatosplenomegaly have been documented [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection

et al. 2010

View full text Add to dashboard Cite

A 69-year-old man suffered from a fractured cervical vertebra, and magnetic resonance imaging revealed a solitary mass occupying the injured lesion. Surgical resection of the mass was conducted, and the infiltration of plasma cells expressing IgE-lambda monoclonal protein was shown on pathological investigation. Concurrently, a monoclonal band of IgE-lambda was shown in the sera on immunoelectrophoresis, and the proliferation of plasma cells (more than 10%) was also detected in bone marrow aspirates. A rare IgE-multiple myeloma (MM) was diagnosed, and careful monthly follow-up was started. During this observation period, the level of IgE gradually increased and, at 2 years after the initial diagnosis, bilateral leg edema and ascites with marked hepatosplenomegaly appeared. Combination chemotherapy of melphalan and prednisolone (MP) was started, which resulted in the partial, transient resolution of symptoms. Additional treatment with bortezomib and dexamethasone could neither resolve these clinical symptoms nor decrease the serum IgE concentration. At 5 months after the start of chemotherapy, amyloid deposition was suggested based on typical echocardiographic findings, and the diagnosis of amyloidosis was confirmed based on the histopathology of a liver biopsy. In spite of MP plus thalidomide treatment, cardiac failure due to amyloidosis aggravated, and the patient died of multiple organ failure. This is the second reported case in which IgE-MM was complicated by systemic amyloidosis.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection

et al. 2010

View full text Add to dashboard Cite

show abstract

“…18 As with common myelomas there was a small tail of long-term survivors confirming the few case reports of prolonged survival in this condition [19][20][21] and also in IgE myeloma. 22 Of note, the proportion of patients receiving TBI was higher among subjects with IgD myeloma than among those with common myelomas or all of the other rare myelomas and while this was associated with a poorer outcome, 13 it was not sufficient to account for the 19-month difference in overall survival of all patients with IgD myeloma. In fact patients with IgD had higher rates of complete remission both before and after transplantation, but unfortunately this did not translate into a better overall survival due to their very high relapse rate.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and outcome of autologous transplantation in rare myelomas

Morris¹,

Drake²,

Apperley³

et al. 2010

Haematologica

View full text Add to dashboard Cite

BackgroundAs rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their prognosis in the era of peripheral stem cell transplantation. Design and MethodsWe used the European Group for Blood and Marrow Transplantation Myeloma Database to compare the outcome following autologous transplantation of over 20,000 patients with common myelomas (IgG, IgA and light chain myeloma) with the outcome of patients with rare myelomas: 379 IgD, 13 IgE, 72 IgM and 976 non-secretory cases. ResultsThe study confirms the multiple adverse prognostic factors seen in IgD myeloma. Somewhat surprisingly, patients with IgD and non-secretory myeloma both had higher complete remission rates before and after transplantation than patients with common myelomas. However, while the overall survival of patients with non-secretory myeloma was similar to that of the patients with common myelomas, the survival of patients with IgD myeloma was significantly worse (although better than survival rates reported for non-transplanted patients); this was due to higher transplant-related mortality and relapse/progression rates. The post-transplantation survival of patients with IgE or IgM myeloma appears to be very poor. ConclusionsThis study provides data on the biological features of rare myelomas. The overall survival of patients with IgD, IgE or IgM myeloma is poor following autologous transplantation but substantially better than that reported for patients who were not transplanted. Key words: rare myelomas, autologous transplantation, outcome, efficacy. . Haematologica 2010;95(12):2126-2133. doi:10.3324/haematol.2010 This is an open-access paper. © F e r r a t a S t o r t i F o u n d a t i o n Citation: Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau J-L, Morgan G, de Witte T, Niederwieser D, and Gahrton G for the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT. Efficacy and outcome of autologous transplantation in rare myelomas Efficacy and outcome of autologous transplantation in rare myelomas

show abstract

“…Since the first case of IgE PCM reported in 1967 [2], there have been only 47 cases of IgE PCM described in the English literature [2][3][4][5][6][7][8][9][10]. Aside from the typical clinical presentations of PCM, rare cases of IgE PCM involving the skin, breast, and orbit have also been reported [8,11,12].…”

Section: Introductionmentioning

confidence: 99%

A rare and unique case of aggressive IgE-λ plasma cell myeloma in a 28-year-old woman presented initially as an orbital mass

Yan

et al. 2012

Human Pathology

View full text Add to dashboard Cite

Low IgE monoclonal gammopathy level in serum highlights 20‐yr survival in a case of IgE multiple myeloma

Cited by 12 publications

References 14 publications

An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection

An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection

Efficacy and outcome of autologous transplantation in rare myelomas

A rare and unique case of aggressive IgE-λ plasma cell myeloma in a 28-year-old woman presented initially as an orbital mass

Contact Info

Product

Resources

About